国内HIV抗病毒治疗依从性预测模型建立

2012-11-27 张芸 中国科学报

  近日,艾滋病患者刘某收到解放军第302医院护理人员发的一条手机短信:“刘大哥,您好!最近身体状况怎么样?别忘了按时吃药。常联系!”这是该院感染性疾病诊疗与研究中心根据建立的HIV感染者抗病毒治疗依从性预测模型评估出的结果,对刘某进行护理干预的一项内容。   据悉,该模型的建成填补了国内此类研究领域的空白,为医护人员有针对性地指导和干预患者抗病毒治疗提供了科学依据。   从2009年开始,3

  近日,艾滋病患者刘某收到解放军第302医院护理人员发的一条手机短信:“刘大哥,您好!最近身体状况怎么样?别忘了按时吃药。常联系!”这是该院感染性疾病诊疗与研究中心根据建立的HIV感染者抗病毒治疗依从性预测模型评估出的结果,对刘某进行护理干预的一项内容。

  据悉,该模型的建成填补了国内此类研究领域的空白,为医护人员有针对性地指导和干预患者抗病毒治疗提供了科学依据。

  从2009年开始,302医院便成立课题组,以HIV感染者抗病毒治疗依从性为研究重点,致力于建立一套科学有效的评估、监测和后续支持体系,在患者接受抗病毒治疗前,对其依从性作出全面预测评估,以便医护人员有针对性地对其进行心理疏导、医疗指导、加强随访等干预性治疗和护理



版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1951680, encodeId=9c43195168076, content=<a href='/topic/show?id=dcfc6458314' target=_blank style='color:#2F92EE;'>#治疗依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64583, encryptionId=dcfc6458314, topicName=治疗依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Fri Nov 08 17:04:00 CST 2013, time=2013-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262699, encodeId=73a1126269973, content=<a href='/topic/show?id=52941002359d' target=_blank style='color:#2F92EE;'>#预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100235, encryptionId=52941002359d, topicName=预测模型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Nov 29 03:04:00 CST 2012, time=2012-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292281, encodeId=a72f1292281e3, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Thu Nov 29 03:04:00 CST 2012, time=2012-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292784, encodeId=5da11292e84e3, content=<a href='/topic/show?id=9d23554e95a' target=_blank style='color:#2F92EE;'>#抗病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55479, encryptionId=9d23554e95a, topicName=抗病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Thu Nov 29 03:04:00 CST 2012, time=2012-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319233, encodeId=84a4131923327, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Thu Nov 29 03:04:00 CST 2012, time=2012-11-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1951680, encodeId=9c43195168076, content=<a href='/topic/show?id=dcfc6458314' target=_blank style='color:#2F92EE;'>#治疗依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64583, encryptionId=dcfc6458314, topicName=治疗依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Fri Nov 08 17:04:00 CST 2013, time=2013-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262699, encodeId=73a1126269973, content=<a href='/topic/show?id=52941002359d' target=_blank style='color:#2F92EE;'>#预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100235, encryptionId=52941002359d, topicName=预测模型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Nov 29 03:04:00 CST 2012, time=2012-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292281, encodeId=a72f1292281e3, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Thu Nov 29 03:04:00 CST 2012, time=2012-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292784, encodeId=5da11292e84e3, content=<a href='/topic/show?id=9d23554e95a' target=_blank style='color:#2F92EE;'>#抗病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55479, encryptionId=9d23554e95a, topicName=抗病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Thu Nov 29 03:04:00 CST 2012, time=2012-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319233, encodeId=84a4131923327, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Thu Nov 29 03:04:00 CST 2012, time=2012-11-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1951680, encodeId=9c43195168076, content=<a href='/topic/show?id=dcfc6458314' target=_blank style='color:#2F92EE;'>#治疗依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64583, encryptionId=dcfc6458314, topicName=治疗依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Fri Nov 08 17:04:00 CST 2013, time=2013-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262699, encodeId=73a1126269973, content=<a href='/topic/show?id=52941002359d' target=_blank style='color:#2F92EE;'>#预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100235, encryptionId=52941002359d, topicName=预测模型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Nov 29 03:04:00 CST 2012, time=2012-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292281, encodeId=a72f1292281e3, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Thu Nov 29 03:04:00 CST 2012, time=2012-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292784, encodeId=5da11292e84e3, content=<a href='/topic/show?id=9d23554e95a' target=_blank style='color:#2F92EE;'>#抗病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55479, encryptionId=9d23554e95a, topicName=抗病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Thu Nov 29 03:04:00 CST 2012, time=2012-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319233, encodeId=84a4131923327, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Thu Nov 29 03:04:00 CST 2012, time=2012-11-29, status=1, ipAttribution=)]
    2012-11-29 yahu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1951680, encodeId=9c43195168076, content=<a href='/topic/show?id=dcfc6458314' target=_blank style='color:#2F92EE;'>#治疗依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64583, encryptionId=dcfc6458314, topicName=治疗依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Fri Nov 08 17:04:00 CST 2013, time=2013-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262699, encodeId=73a1126269973, content=<a href='/topic/show?id=52941002359d' target=_blank style='color:#2F92EE;'>#预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100235, encryptionId=52941002359d, topicName=预测模型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Nov 29 03:04:00 CST 2012, time=2012-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292281, encodeId=a72f1292281e3, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Thu Nov 29 03:04:00 CST 2012, time=2012-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292784, encodeId=5da11292e84e3, content=<a href='/topic/show?id=9d23554e95a' target=_blank style='color:#2F92EE;'>#抗病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55479, encryptionId=9d23554e95a, topicName=抗病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Thu Nov 29 03:04:00 CST 2012, time=2012-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319233, encodeId=84a4131923327, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Thu Nov 29 03:04:00 CST 2012, time=2012-11-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1951680, encodeId=9c43195168076, content=<a href='/topic/show?id=dcfc6458314' target=_blank style='color:#2F92EE;'>#治疗依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64583, encryptionId=dcfc6458314, topicName=治疗依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Fri Nov 08 17:04:00 CST 2013, time=2013-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262699, encodeId=73a1126269973, content=<a href='/topic/show?id=52941002359d' target=_blank style='color:#2F92EE;'>#预测模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100235, encryptionId=52941002359d, topicName=预测模型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Thu Nov 29 03:04:00 CST 2012, time=2012-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292281, encodeId=a72f1292281e3, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Thu Nov 29 03:04:00 CST 2012, time=2012-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292784, encodeId=5da11292e84e3, content=<a href='/topic/show?id=9d23554e95a' target=_blank style='color:#2F92EE;'>#抗病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55479, encryptionId=9d23554e95a, topicName=抗病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Thu Nov 29 03:04:00 CST 2012, time=2012-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319233, encodeId=84a4131923327, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Thu Nov 29 03:04:00 CST 2012, time=2012-11-29, status=1, ipAttribution=)]
    2012-11-29 fyxzlh

相关资讯

Nat Medicine:新型研究或可解释为何艾滋病疫苗难以成功研发

数年来,成功的HIV疫苗对于研究者来说如同耶稣手中的圣杯一样难以得到,尽管这些年来花费了众多的人力物力,成功的HIV疫苗仍未开发出来。但是近来俄勒冈医科大学的研究者揭示了含有毒力弱化的AIDS病毒的猴子为何可以抵御完整强毒株HIV的接二连三的感染。但是这种方法对于人类来说是有一定风险的。 相关研究成果刊登在了近日的国际杂志Nature Medicine上。 一般情况下有两种方法来开发新型疫苗抵

CID:垂直感染HIV青少年心脏病负担重

  一项多国联合研究表明,垂直感染人类免疫缺陷病毒(HIV)的青少年心脏病负担显著。论文10月24日在线发表于《临床传染病》(Clin Infect Dis)杂志。   研究纳入110例垂直感染HIV的青少年(47%为男性,中位年龄15岁),评估病史、体格检查和多普勒超声心动图情况。   结果为,78例(71%)感染者接受抗逆转录病毒治疗(ART)。劳力性呼吸困难、胸痛、心

美国预防服务工作组HIV筛查推荐草案发布

  11月20日,美国预防服务工作组(USPSTF)在其网站发表一项推荐草案声明,强烈推荐所有年龄在15岁至65岁人群进行艾滋病病毒(HIV)筛查。声明还建议所有孕妇,以及处于HIV高危风险中的不到15岁的青少年和大于65岁的老年人进行HIV筛查。   专家组成员欧文斯指出,该推荐草案反映了筛查和早期治疗HIV益处的新证据。由于在感染艾滋病病毒的早期通常没有症状,人们需要经过筛查了解他们是否已被

AIDS and Behavior :HIV家用检测试纸可预防艾滋传播

30年来对HIV流行病学的监控表明,许多HIV感染高风险者不能或不愿采取安全性行为,比如禁欲和使用安全套。这些情况表明在这些(高风险)个体中采取替代方法降低HIV暴露率或传播率有市场空间。纽约艾滋病临床与行为研究中心 Alex Carballo-Dieguez与其同事最近的一个研究项目结果----- HIV家用检测试纸(HT)就是这样的方法之一。 Springer旗下的《AIDS and

JAMA:大剂量多种维生素补充剂不能减少接受HAART患者死亡率

  据发表在10月17日发表在《美国医学会杂志》上的一项研究披露,在坦桑尼亚的感染了人类免疫缺陷性病毒(HIV)的病人中,与给予标准剂量的多种维生素补充剂相比,在开始具有高度活性的抗逆转录病毒疗法后给予高剂量的多种维生素补充剂不会减少HIV疾病进展的风险或死亡率,但却会导致某种肝脏酶水平增高的不良反应。   根据文章的背景资料:“在过去的15年间提供具有高度活性的抗逆转录病毒疗法(HAART)显

AIM:白人与非白人的HIV死亡率差异增大

  根据10月8日发表于《内科学文献》(Archives of Internal Medicine)的一篇报告,自上世纪90年代中期以来,除教育水平较低的非西班牙裔黑人之外,其他所有人口群体的HIV相关死亡率均有显着降低。这种时间趋势不可避免地造成白人与非白人的HIV死亡率差异增大。   HIV已成为黑人中日益重要的死亡原因,与此同时,其在白人死亡原因中的重要性却正在降低。作者指出,近年来的数据